This analysis examines Advanced Enzyme (ADVENZYMES) through the lens of its financial statements, valuation metrics, and institutional ownership patterns.
Advanced Enzyme Revenue Trend
The numbers weren't encouraging on the revenue front: Advanced Enzyme reported ₹637 Cr in FY2025, 3.6% below FY2024 levels.
Revenue compounded at 11.1% annually over 10 years for Advanced Enzyme. That's a strong growth rate that comfortably outpaces inflation.
At ₹637 Cr in annual revenue, Advanced Enzyme is one of the smaller players in the pharmaceuticals space.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹637 Cr | -3.6% |
| FY2024 | ₹661 Cr | +16.7% |
| FY2023 | ₹566 Cr | +5.7% |
| FY2022 | ₹536 Cr | +6.8% |
| FY2021 | ₹502 Cr | — |
View Advanced Enzyme's full 10-year revenue trend with CAGR analysis →
Advanced Enzyme Profitability
Profitability was under pressure with net income dropping 4.3% to ₹131 Cr in FY2025.
Not much change on the margin front — net profit margin held at roughly 20.6% in FY2025.
Looking at per-share numbers, diluted EPS was ₹11.71 in FY2025 — down from ₹11.92.
Is Advanced Enzyme Undervalued
The P/E Ratio approach puts Advanced Enzyme's intrinsic value at ₹329, a 13.5% downside from the current market price.
Advanced Enzyme shares are currently trading at ₹380.25.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹329 | 13.5% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Advanced Enzyme with detailed assumptions →
Advanced Enzyme Shareholding Pattern
Promoter holding is steady at 43.3% — no buying or selling over the past 4 quarters.
Foreign institutional investors (FIIs) held 25.5% as of March 2026, up from 23.5% a year ago.
DII holding is at 5.4%, down from 8.4% in the year-ago quarter.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 43.3% | 25.5% | 5.4% | 25.8% |
| Dec 2025 | 43.0% | 25.9% | 5.5% | 25.6% |
| Sep 2025 | 43.1% | 25.4% | 6.4% | 25.1% |
| Jun 2025 | 43.1% | 23.5% | 8.4% | 25.0% |
Track quarterly shareholding changes for Advanced Enzyme →
Advanced Enzyme Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹16.21B (up 5.6% YoY from ₹15.35B).
Top categories: Cash & ST Investments (35.4%), Intangibles & Goodwill (23.8%), Property, Plant & Equipment (19.4%).
Of the ₹16.21B in liabilities and equity, 90.6% is shareholder equity, 2.4% is interest-bearing debt, and 7.0% is operating liabilities. Over the year, debt is down 16.8% and equity is up 7.1%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 5.74B |
| Receivables | 1.15B |
| Inventories | 1.57B |
| Property, Plant & Equipment | 3.15B |
| Investments | 650,000 |
| Intangibles & Goodwill | 3.86B |
| Other Assets | 737.15M |
| Category | Value |
|---|---|
| Equity | 14.69B |
| Short-term Debt | 184.33M |
| Long-term Debt | 209.17M |
| Trade Payables | 172.01M |
| Other Liabilities | 961.26M |
Advanced Enzyme Key Highlights
Here's the bottom line on Advanced Enzyme (ADVENZYMES) based on the latest available financials.
Revenue of ₹637 Cr in FY2025, down 3.6% year-over-year.
Long-term revenue has been compounding at 11.1% annually over 10 years.
The company is profitable, with a net margin of 20.6% and net income of ₹131 Cr.
The P/E Ratio model implies 13.5% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Advanced Enzyme.